Open An Account
Best Online Share Trading and Investing Broker in India | mastertrust

Ipca Laboratories Ltd.

BSE : 124494 NSE : IPCALAB ISIN : INE571A01038 Industry : Pharmaceuticals & Drugs
689.10
B S Sip
Change: 4.65 (0.68 %)
As on 29-May-2023 12:00 AM
Advance Chart
Prev.Close 684.45
Open 686.45
Day's High 691.35
Day's Low 675.45
Mkt.Cap ( Cr.) 17,482.74
Face Value 1.00
PE Ratio 37.09
PB Ratio 4.87

52 Week High Low

Low: 669.80
High: 1,034.30
LTP:689.10

Lifetime High Low

Low: 2.75
High: 1,383.10
LTP:689.10

Ipca Laboratories Ltd.

BSE : 124494 NSE : IPCALAB ISIN : INE571A01038 Industry : Pharmaceuticals & Drugs
688.95
B S Sip
Change: 5.35 (0.78 %)
As on 29-May-2023 12:00 AM
Advance Chart
Prev.Close 683.60
Open 689.95
Day High 691.00
Day Low 675.95
Mkt.Cap ( Cr. ) 17,478.94
Face Value 1.00
P/E Ratio 37.09
PB Ratio 4.87

52 Week High Low

Low:670.00
High:1,033.50
LTP:688.95

Lifetime High Low

Low:2.83
High:1,383.55
LTP:688.95
Advance Chart

P/E Ratio

52 W L(14.96)
52 W H(40.26)

P/E Ratio

52 W L(14.96)
52 W H(40.26)
Had I Invested a sum of 1,00,000 on the same day 5 years ago,the money would have become 199941.97 ( a of 14.86 p.a.)

Key Levels and Moving Averages

Take a quick peak at the technical support and resistance levels of the stock price along with various moving average numbers automatically calculated for you

Key Levels

Support Level 1 679.37
Support Level 2 674.28
Resistance Level 1 687.72
Resistance Level 2 690.98

Moving Average

20 Days 693.79
50 Days 758.95
100 Days 803.01
200 Days 855.35

Peer Companies

Compare the performance of a stock with the other stocks from the same sector

Sotac Pharmaceuticals Ltd. 139.80 Change: 14.80 (11.84%)
PE : 53.66
1Y Return: 0.00%

B S
Bafna Pharmaceuticals Ltd. 97.65 Change: 4.65 (5.00%)
PE : 20.54
1Y Return: -18.49%

B S
Walpar Nutritions Ltd. 86.35 Change: 4.10 (4.98%)
PE : 68.72
1Y Return: 118.33%

B S
Ind-Swift Ltd. 8.80 Change: 0.40 (4.76%)
PE : 0.00
1Y Return: -6.38%

B S
View More

Key Ratios

A quick glance at the key aspects of the company's financial picture such as liquidity, profitability and earnings strength

FY 2022FY 2021FY 2020FY 2019FY 2018
EBDITA Margin (%)24.1330.7222.5020.6515.05
PBT Margin (%)20.1626.8517.9715.348.78
PAT Margin (%)16.1322.2014.9412.527.24
ROCE (%)19.5230.5420.8416.769.53
ROE (%)16.9527.1019.1815.609.02

Profit & Loss

Stay on top of the company’s Quarterly/Half Yearly/Yearly P&L statement to take an in-depth look at a company’s financial performance

FY 2022FY 2021FY 2020FY 2019FY 2018
Total Income ( Cr.)5,478.565,242.714,421.983,677.233,251.10
Gross Profit ( Cr.)1,292.461,567.68963.66729.27457.16
Profit Before Tax ( Cr.)1,088.361,379.96784.97557.39282.80
Tax ( Cr.)217.42239.19132.51102.4849.69
Profit After Tax ( Cr.)870.941,140.77652.46454.91233.11

Shareholding Pattern & Management

NAME DESIGNATION
Premchand Godha Chairman
Premchand Godha Chairman & Managing Director
Ajit Kumar Jain Joint Managing Director
Ajit Kumar Jain Managing Director/CFO
Pranay Godha Executive Director
Pranay Godha Managing Director / CEO
Prashant Godha Executive Director
Anand T Kusre Non Executive Independent Director
Dev Parkash Yadava Non Executive Independent Director
Manisha Premnath Non Executive Independent Director
Kamal Kishore Seth Non Executive Independent Director
Harish P Kamath Corporate Counsel & Company Secretary
Narendra Mairpady Independent Director

Corporate Action

Stay abreast of the latest bonus, dividend and other corporate action news of the company to take informed investment decisions

No Data Available

MF Holding

Take a peek into the mutual funds, which hold the stock in their portfolio as of the last reported quarter

Scheme Name AUM% Value(Rs. Cr.) Holding Date
HDFC Mid-Cap Opportunities Fund - Growth Know More 1.97 726.26 30-Apr-2023
Kotak Emerging Equity Fund - Growth Know More 1.77 460.18 30-Apr-2023
DSP Midcap Fund - Regular Plan - Growth Know More 2.89 389.05 30-Apr-2023
Parag Parikh Flexi Cap Fund - Regular Plan - Growth Know More 0.75 251.52 30-Apr-2023
UTI Flexi Cap Fund - Regular Plan - IDCW Know More 0.95 230.32 30-Apr-2023
View More

News

Ipca Laboratories reports Profit after tax of Rs 848.20 Mln, in the March 2023 quarter
Type: CORPORATE RESULT
Date: 29-May-2023 01:40 PM
--
Ipca Laboratories inks pact to acquire 33.4% stake in Unichem Laboratories
Type: NEWS
Date: 24-Apr-2023 04:58 PM
The business and product range of Ipca and that of Unichem complements each others business and product range
Ipca Laboratories reports Profit after tax of Rs 1202.70 Mln, in the December 2022 quarter
Type: CORPORATE RESULT
Date: 14-Feb-2023 01:07 PM
--
Ipca Laboratories gains on acquiring further 6.53% stake in Trophic Wellness
Type: MOVERS TODAY
Date: 20-Dec-2022 12:25 PM
Cash Consideration of Rs 10.58 crore was paid for the additional acquisition of 6.53% shareholding of TWPL
Ipca Laboratories acquires further 6.53% stake in Trophic Wellness
Type: NEWS
Date: 20-Dec-2022 09:21 AM
Cash Consideration of Rs 10.58 crore was paid for the additional acquisition of 6.53% shareholding of TWPL
Ipca Laboratories reports Profit after tax of Rs 1677.80 Mln, in the September 2022 quarter
Type: CORPORATE RESULT
Date: 11-Nov-2022 01:24 PM
--
View More